^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Eylea (aflibercept intravitreal)

    i
    Company:
    Bayer, Regeneron
    Drug class:
    VEGF-A inhibitor, PIGF inhibitor
    Related drugs:
    2d
    A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects with NAMD (clinicaltrials.gov)
    P3, N=600, Active, not recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    8d
    4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=400, Recruiting, 4D Molecular Therapeutics
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    11d
    ARTEMIS: Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=284, Not yet recruiting, Adverum Biotechnologies, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    11d
    VERONA: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=27, Completed, EyePoint Pharmaceuticals, Inc. | Recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal) • Fumena (vorolanib)
    15d
    THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P1/2, N=546, Recruiting, Genentech, Inc.
    New P1/2 trial
    |
    Eylea (aflibercept intravitreal)
    17d
    DAPA-DME: Randomized Clinical Trial to Evaluate the Effect of Dapagliflozin in Patients with Diabetic Macular Edema (clinicaltrials.gov)
    P2, N=56, Recruiting, Alexandria University
    New P2 trial
    |
    Eylea (aflibercept intravitreal) • Farxiga (dapagliflozin)
    22d
    Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Beijing Anlong Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    A Long-term Follow Up Study of EXG102-031 in Patients with WAMD (Everest LTFU) (clinicaltrials.gov)
    P1, N=12, Enrolling by invitation, Exegenesis Bio
    New P1 trial
    |
    Eylea (aflibercept intravitreal)
    1m
    Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration (clinicaltrials.gov)
    P1, N=45, Recruiting, Caregen Co. Ltd. | Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Aug 2025 | Trial primary completion date: Oct 2024 --> May 2025
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    1m
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=51, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    1m
    OTX-TKI-2023-AMD-301: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=344, Active, not recruiting, Ocular Therapeutix, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    1m
    A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK (clinicaltrials.gov)
    P3, N=675, Recruiting, Kodiak Sciences Inc | Trial completion date: Jan 2026 --> Apr 2027 | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    2ms
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Recruiting, Bayer | Trial primary completion date: Mar 2026 --> Oct 2025 | Trial completion date: Mar 2026 --> Oct 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    2ms
    PHOTONiC: A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema (clinicaltrials.gov)
    P3, N=333, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | Trial primary completion date: May 2026 --> Dec 2025
    Enrollment closed • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    2ms
    VOYAGE: Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial (clinicaltrials.gov)
    P4, N=41, Completed, Greater Houston Retina Research | Active, not recruiting --> Completed | N=150 --> 41
    Trial completion • Enrollment change
    |
    Eylea (aflibercept intravitreal)
    2ms
    DME HOME: Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT (clinicaltrials.gov)
    P=N/A, N=308, Recruiting, Zhongshan Ophthalmic Center, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open • Head-to-Head
    |
    Eylea (aflibercept intravitreal)
    2ms
    Phase 1 randomised controlled clinical trial testing the safety and efficacy of CPP-anti-VEGF for the treatment of neovascular age-related macular degeneration (ChiCTR2400093162)
    P1, N=60, Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong; Department of Ophthalmology and Visual Sciences, The Chinese Uni
    New P1 trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    FAR-WEST: Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD. (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Nantes University Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
    2ms
    OTX-TKI-2023-AMD-303: Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration (clinicaltrials.gov)
    P3, N=825, Recruiting, Ocular Therapeutix, Inc. | Initiation date: Jul 2024 --> Nov 2024
    Trial initiation date
    |
    Eylea (aflibercept intravitreal)
    2ms
    ELARA: A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P3, N=1000, Recruiting, Regeneron Pharmaceuticals | N=400 --> 1000
    Enrollment change
    |
    Eylea (aflibercept intravitreal)
    2ms
    A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) (clinicaltrials.gov)
    P=N/A, N=550000, Not yet recruiting, Regeneron Pharmaceuticals
    New trial
    |
    Eylea (aflibercept intravitreal)
    2ms
    ODYSSEY: Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P2, N=60, Completed, Clearside Biomedical, Inc. | Active, not recruiting --> Completed | Phase classification: P2b --> P2
    Trial completion • Phase classification
    |
    Eylea (aflibercept intravitreal) • axitinib injectable suspension (CLS-AX)
    3ms
    EYP-1901-302: A 2-year Study of EYP-1901 in Subjects with Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will Be Determined At Week 52 (clinicaltrials.gov)
    P3, N=400, Recruiting, EyePoint Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    3ms
    QUASAR: A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (clinicaltrials.gov)
    P3, N=822, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    3ms
    Comparing Intravitreal Aflibercept Monotherapy Vs Aflibercept Combined with Reduced Fluence PDT in PCV Treatment (clinicaltrials.gov)
    P=N/A, N=60, Completed, Singapore National Eye Centre | Active, not recruiting --> Completed
    Trial completion
    |
    Visudyne (verteporfin) • Eylea (aflibercept intravitreal)
    3ms
    A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects with Neovascular Age-Related Macular Degeneration (clinicaltrials.gov)
    P3, N=434, Not yet recruiting, Rophibio, Inc. | Initiation date: Sep 2024 --> Jan 2025
    Trial initiation date
    |
    Eylea (aflibercept intravitreal)
    4ms
    Ocular Safety and Usability Study for FYB203 PFS (clinicaltrials.gov)
    P4, N=30, Completed, Formycon AG
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    4ms
    OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov)
    P=N/A, N=80, Recruiting, Medical University of Vienna | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Sep 2023 --> Nov 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal) • Lucentis (ranibizumab)
    4ms
    SPECTRUM-US: An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Regeneron Pharmaceuticals | N=800 --> 0 | Initiation date: Aug 2024 --> Dec 2024 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial initiation date • Trial withdrawal • Real-world evidence • Real-world
    |
    Eylea (aflibercept intravitreal)
    4ms
    Mean Visual Acuity Changes Following Five Injections of Aflibercept (clinicaltrials.gov)
    P=N/A, N=48, Active, not recruiting, McMaster University | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    Eylea (aflibercept intravitreal)
    4ms
    FAN: Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=70, Active, not recruiting, Medical University of Graz | Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Mar 2025
    Trial completion date • Trial primary completion date
    |
    VEGFA (Vascular endothelial growth factor A)
    |
    Eylea (aflibercept intravitreal)
    4ms
    A Study of IBI302 in Patients With nAMD (clinicaltrials.gov)
    P2, N=231, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    4ms
    A 2-year Study of EYP-1901 in Subjects with Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will Be Determined At Week 52 (clinicaltrials.gov)
    P3, N=400, Not yet recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    4ms
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal)
    4ms
    PRISM: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration (clinicaltrials.gov)
    P1/2, N=215, Recruiting, 4D Molecular Therapeutics | N=150 --> 215 | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    5ms
    A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO). Primary Efficacy Will be Determined at Week 52. (clinicaltrials.gov)
    P3, N=400, Recruiting, EyePoint Pharmaceuticals, Inc.
    New P3 trial
    |
    Eylea (aflibercept intravitreal)
    5ms
    ASCENT: Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (clinicaltrials.gov)
    P3, N=660, Recruiting, AbbVie | N=465 --> 660 | Trial completion date: Dec 2025 --> Nov 2026 | Trial primary completion date: Feb 2025 --> Nov 2025
    Enrollment change • Trial completion date • Trial primary completion date • Gene therapy
    |
    Eylea (aflibercept intravitreal)
    6ms
    Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE) (clinicaltrials.gov)
    P3, N=413, Completed, Alvotech Swiss AG | Active, not recruiting --> Completed
    Trial completion
    |
    Eylea (aflibercept intravitreal)
    6ms
    DME HOME: Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT (clinicaltrials.gov)
    P=N/A, N=308, Not yet recruiting, Zhongshan Ophthalmic Center, Sun Yat-sen University
    New trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) (clinicaltrials.gov)
    P2, N=52, Active, not recruiting, Unity Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Eylea (aflibercept intravitreal)
    6ms
    DEUTERON: A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration (clinicaltrials.gov)
    P4, N=45, Not yet recruiting, Bayer
    New P4 trial
    |
    Eylea (aflibercept intravitreal)
    6ms
    VERONA: Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) (clinicaltrials.gov)
    P2, N=25, Recruiting, EyePoint Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Eylea (aflibercept intravitreal) • Fumena (vorolanib)